CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.
Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR工程化T细胞被称为“活药物”。加入共刺激结构域可增强CAR-T 抗血液肿瘤作用,促进其临床应用。不同共刺激结构域已用于构建CAR-T 并研究抗肿瘤效果,但其影响功能的分子机制报道较少。虽然共刺激结构域在T细胞中的作用已被广泛研究,它们在CAR结构中是否发挥独特功能仍不清楚。本文基于有限文献总结不同共刺激结构域对CAR-T 信号通路的影响,并结合CAR-T 特征推测可能机制。综述有助于理解不同结构域导致抗肿瘤效应差异的分子基础,并为后续干预、增强免疫治疗效果提供参考。
Chimeric antigen receptor (CAR)-engineered T cells have been defined as 'living drug'. Adding a co-stimulatory domain (CSD) has enhanced the anti-hematological effects of CAR-T cells, thereby elevating their viability for medicinal applications. Various CSDs have helped prepare CAR-T cells to study anti-tumor efficacy. Previous studies have described and summarized the anti-tumor efficacy of CAR-T cells obtained from different CSDs.
However, the underlying molecular mechanisms by which different CSDs affect CAR-T function have been rarely reported. The role of CSDs in T cells has been significantly studied, but whether they can play a unique role as a part of the CAR structure remains undetermined.
Here, we summarized the effects of CSDs on CAR-T signaling pathways based on the limited references and speculated the possible mechanism depending on the specific characteristics of CAR-T cells. This review will help understand the molecular mechanism of CSDs in CAR-T cells that exert different anti-tumor effects while providing potential guidance for further interventions to enhance anti-tumor efficacy in immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。